Edition:
United Kingdom

People: Yield10 Bioscience Inc (YTEN.OQ)

YTEN.OQ on NASDAQ Stock Exchange Capital Market

0.92USD
16 Aug 2019
Change (% chg)

$-0.03 (-3.02%)
Prev Close
$0.95
Open
$0.95
Day's High
$0.95
Day's Low
$0.88
Volume
27,945
Avg. Vol
30,309
52-wk High
$1.76
52-wk Low
$0.68

Haaser, Charles 

Mr. Charles B. Haaser is a Chief Accounting Officer, Vice President - Finance of the Company. Mr. Haaser became the Company's Chief Accounting Officer effective November 3, 2014, after serving as the Company’s Corporate Controller since 2008. Mr. Haaser has more than thirty years of experience in accounting and finance, primarily working for publicly traded U.S. companies. Before joining Metabolix, Mr. Haaser was the Corporate Controller of Indevus Pharmaceuticals, Inc. from 2006 to 2008. He was the Corporate Controller and Principal Accounting Officer at ABIOMED, Inc. from 1998 to 2006 and additionally served as ABIOMED’s Acting Chief Financial Officer from 2003 to 2006. From 1997 to 1998 Mr. Haaser was controller for Technical Communications Corporation and from 1986 to 1997 was the Director of Finance at ISI Systems, Inc. From 1984 to 1986 Mr. Haaser was an auditor in the commercial audit division of Price Waterhouse LLP (now PricewaterhouseCoopers LLP). Mr. Haaser received a bachelor’s degree in business administration (finance) from the University of Notre Dame, an MBA from Northeastern University and a Masters of Science in Taxation from Bentley University. Mr. Haaser became a Certified Public Accountant in 1997.

Basic Compensation

Total Annual Compensation, USD 226,417
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 25,525
Fiscal Year Total, USD 251,942

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --